These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 31845043)

  • 1. The role of melatonin in Multiple Sclerosis.
    Skarlis C; Anagnostouli M
    Neurol Sci; 2020 Apr; 41(4):769-781. PubMed ID: 31845043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corticosteroid therapy exacerbates the reduction of melatonin in multiple sclerosis.
    Dokoohaki S; Ghareghani M; Ghanbari A; Farhadi N; Zibara K; Sadeghi H
    Steroids; 2017 Dec; 128():32-36. PubMed ID: 29061489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis.
    Ghareghani M; Zibara K; Sadeghi H; Farhadi N
    Cell Mol Neurobiol; 2018 Jul; 38(5):1145-1151. PubMed ID: 29497878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis.
    Chen SJ; Huang SH; Chen JW; Wang KC; Yang YR; Liu PF; Lin GJ; Sytwu HK
    Int Immunopharmacol; 2016 Feb; 31():169-77. PubMed ID: 26735612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
    Escribano BM; Muñoz-Jurado A; Caballero-Villarraso J; Valdelvira ME; Giraldo AI; Paz-Rojas E; Gascón F; Santamaría A; Agüera E; Túnez I
    Mult Scler Relat Disord; 2022 Feb; 58():103520. PubMed ID: 35038645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis.
    Wen J; Ariyannur PS; Ribeiro R; Tanaka M; Moffett JR; Kirmani BF; Namboodiri AM; Zhang Y
    J Neuroimmune Pharmacol; 2016 Dec; 11(4):763-773. PubMed ID: 27562847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis.
    Penkowa M; Hidalgo J
    J Neurosci Res; 2003 Jun; 72(5):574-86. PubMed ID: 12749022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application.
    Severa M; Zhang J; Giacomini E; Rizzo F; Etna MP; Cruciani M; Garaci E; Chopp M; Coccia EM
    Mult Scler Relat Disord; 2019 Jan; 27():52-60. PubMed ID: 30317071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis.
    Schmitz K; Brunkhorst R; de Bruin N; Mayer CA; Häussler A; Ferreiros N; Schiffmann S; Parnham MJ; Tunaru S; Chun J; Offermanns S; Foerch C; Scholich K; Vogt J; Wicker S; Lötsch J; Geisslinger G; Tegeder I
    Acta Neuropathol Commun; 2017 Jun; 5(1):42. PubMed ID: 28578681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
    Messina S
    Small GTPases; 2020 Sep; 11(5):312-319. PubMed ID: 30043672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mice overexpressing Bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE).
    Offen D; Kaye JF; Bernard O; Merims D; Coire CI; Panet H; Melamed E; Ben-Nun A
    J Mol Neurosci; 2000 Dec; 15(3):167-76. PubMed ID: 11303781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis.
    Mirowska-Guzel D
    Immunopharmacol Immunotoxicol; 2009; 31(1):32-8. PubMed ID: 18792835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory effects of melatonin in multiple sclerosis.
    Farez MF; Calandri IL; Correale J; Quintana FJ
    Bioessays; 2016 Oct; 38(10):1016-26. PubMed ID: 27561251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nudging oligodendrocyte intrinsic signaling to remyelinate and repair: Estrogen receptor ligand effects.
    Khalaj AJ; Hasselmann J; Augello C; Moore S; Tiwari-Woodruff SK
    J Steroid Biochem Mol Biol; 2016 Jun; 160():43-52. PubMed ID: 26776441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective Effects of Melatonin on Experimental Allergic Encephalomyelitis Mice Via Anti-Oxidative Stress Activity.
    Long T; Yang Y; Peng L; Li Z
    J Mol Neurosci; 2018 Feb; 64(2):233-241. PubMed ID: 29450696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppressed oligodendrocyte steroidogenesis in multiple sclerosis: Implications for regulation of neuroinflammation.
    Boghozian R; McKenzie BA; Saito LB; Mehta N; Branton WG; Lu J; Baker GB; Noorbakhsh F; Power C
    Glia; 2017 Oct; 65(10):1590-1606. PubMed ID: 28707358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE).
    Ziemssen T; Ziemssen F
    Autoimmun Rev; 2005 Sep; 4(7):460-7. PubMed ID: 16137612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis.
    Ghareghani M; Scavo L; Arnoult D; Zibara K; Farhadi N
    Fundam Clin Pharmacol; 2018 Apr; 32(2):181-187. PubMed ID: 29193274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.
    Nimmagadda VK; Makar TK; Chandrasekaran K; Sagi AR; Ray J; Russell JW; Bever CT
    J Neuroimmunol; 2017 Mar; 304():29-34. PubMed ID: 27474445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?
    Lee DH; Linker RA
    Expert Opin Ther Targets; 2012 May; 16(5):451-62. PubMed ID: 22494461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.